OrbiMed’s Teva Pharmaceuticals TEVA Stock Holding History

OrbiMed’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-100,000	Closed	-$5.24M	–	142
2014 Q2	$5.24M	Buy	+100,000	New	+$5.11M	0.06%	109

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

OrbiMed's TEVA Position: Q1 2021 in Review

OrbiMed sold out of Teva Pharmaceuticals (TEVA) in Q1 2021, closing a stake of 1,935,200 shares — an estimated $18.7M sold.

OrbiMed first reported a position in TEVA in Q3 2014 and held it in 17 quarters. The position peaked at $161M in Q4 2015. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

OrbiMed reported no remaining Teva Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
OrbiMed sold 1,935,200 Teva Pharmaceuticals shares in Q1 2021, an estimated $18.7M.
OrbiMed first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 17 quarters.
OrbiMed's Teva Pharmaceuticals position peaked at $161M in Q4 2015.
451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.